Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus

The combination of chronic coronary heart disease and type 2 diabetes mellitus in a patient has high medical importance, because relevance of the problem increases every year. Modern requirements for the provision of high-quality medical care to patients with combined pathology require attentive assessment: we can’t deny the pathophysiological relationship of both diseases. Serious changes that occurred in the treatment tactics in relation to such patients require close attention of the medical community. Modern approaches of the therapy of this group of patients include treatment directions that improve the cardiovascular prognosis (lifestyle changes, anti-platelet therapy, antihypertensive therapy, statins and nonstatin lipid-lowering agents, which are indicated for patients who are difficult to tolerate statin treatment, glucose-lowering drugs), as well as careful management of stable angina syndrome (using of antianginal drugs, assessing the possibilities of revascularization). The therapeutic tactics of the new revision offers promising perspective regimens for taking antiplatelet therapy, lipid-lowering drugs. The new line of glucose-lowering drugs has high cardioprotective properties, reduces the intensity of vascular lesions (vasoprotection), and has renoprotective properties. The strategy of choosing glucose-lowering drugs has also undergone some changes: at the moment it is designated as «differentiated», which implies choosing a drug with the highest organoprotective properties. Achievement of target HbA1C levels in the range of 7.0-8.0 % is associated with the lowest patient mortality rate. In addition, to patients with type 2 diabetes mellitus, especially group with coronary heart disease, advised to minimize episodes of hypoglycemic conditions. Aim of this statement is to discuss in detail progressive approaches in the treatment of patients with chronic coronary heart disease and type 2 diabetes mellitus.

1. Ferrannini G, De Bacquer D, De Backer G, et al. EUROASPIRE V collaborators. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease — a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V. Diabetes Care. 2020;43(4): 726–733. doi:10.2337/dc19-2165.

2. Ferranini G., Norhammar A., Gyberg V. et al. Is coronary artery disease inevitable in type 2 diabetes? From a glucocentric to a holistic view on patient management. Diabetes Care. 2020; 43 (9): 2001-2009. doi: 10.2337/dci20-0002.

3. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: 596–646. doi: 10.1161/CIR.0000000000000678

4. Evert AB, Dennison M, Gardner CD et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019; 42(5): 731-754. doi:10.2337/dci19-0014

5. Boer de L., Caramori M., Chan J. et al. Executive summary of the 2020 KDIGO Diabetes management in CKD Guideline: Evidence-based advances in monitoring and treatment. Kidney Int.2020; 98: 839–848. doi:10.1016/j.kint.2020.06.024

6. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020; 141: 779–806. doi: 10.1161/CIR.0000000000000766

7. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016; 39: 2065–2079. doi: 10.2337/dc16-1728

8. Newman J.D., Schwartzbard A.Z., Weintraub H.S., et al. Primary prevention of cardiovascular disease in diabetes mellitus. JACC. 2017; 70(7): 883-893. doi: 10.1016/j.jacc.2017.07.001

9. Cosentino F. GPJ, Aboyans V., Bailey C.J. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal. 2020; 41(2): 255-323. doi:10.1093/eurheartj/ehz486.

10. Bates E.R. Antiplatelet therapy in patients with coronary disease and type 2 diabetes. N Engl J Med. 2019; 381(14): 1373-1375. doi: 10.1056/NEJMe1910813

11. Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022; 145: 722–759. doi:10.1161/CIR.0000000000001040.

12. Connolly SJ, Eikelboom JW, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205–218. doi: 10.1016/S0140-6736(17)32458-3

13. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes. 2020. Diabetes Care. 2020; 43(1): 111–134. doi.org/10.2337/dc20-s010

14. Deedwania P. The ongoing saga of optimal blood pressure level in patients with diabetes mellitus and coronary artery disease. J Am Heart Assoc. 2018; 7: e010752. doi: 10.1161/JAHA.118.010752

15. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–967. doi: 10.1016/S0140-6736(15)01225-8

16. Goldberg R.B., Stone N.J., Grundy S.M. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. Diabetes Care 2020; 43(8): 1673-1678. doi 10.2337/dci19-0036

17. Berberich A., Hegele R.A. LDL cholesterol: lower, faster, younger? Lancet Diabetes Endocrinology. 2020; 8(1): 5-7. doi:10.1016/S2213-8587(19)30389-4.

18. François M, Colin B, Alberico LC, et. al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020; 41 (1): 111–188. doi.org/10.1093/eurheartj/ehz455

19. Grundy SM, Stone NJ, Bailey AL, et al., 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. Circulation. 2019; 73 (24): 285–350. doi:10.1016/j.jacc.2018.11.003.

20. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57: 2444–2452. doi: 10.1007/s00125-014-3374-x

21. Newman C.B., Preiss D., Tobert J.A. et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association.Arteriosclerosis, Thrombosis and Vascular Biology. 2019; 39(2): 38-81. doi: 10.1161/ATV.0000000000000073.

22. Smolina M.O., Benimeckaja K.S., Ragino Ju.I. PCSK9: new victories and horizons. Atherosclerosis. 2018; 14(3): 70-77. doi: 10.15372/ATER20180311. [In Russian]

23. Landmesser U, Chapman MJ, Stock JK et al. 2017 Update of ESC/ EAS Task Force on Practical Clinical Guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39: 1131–1143. doi: 10.1093/eurheartj/ehx549

24. Bowman L., Mafham M., Wallendszus K. et al. Effects of n-3 fatty acid supplements in diabetes mellitus . N Engl J Med. 2018; 379: 1540-50. doi: 10.1056/NEJMoa1804989

25. Bhatt DL, Steg PG, Miller M et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapentethyl for hypertriglyceridemia. N Engl J Med. 2019; 380: 11–22. doi: 10.1056/NEJMoa1812792

26. Abhinav Sharma, Neha J. Pagidipati, et al. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus Lessons Learned and Future Directions. Circulation. 2020; 141: 843–862. doi: 10.1161/CIRCULATIONAHA.119.041022

27. American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020; 43(1): 66–76. doi:10.2337/dc20-S006.

28. Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018; 41: 104–111. doi: 10.2337/dc17-1669

29. Vorozhcova I.N., Budnikova O.V., Afanas’ev S.A. The effect of type 2 diabetes mellitus on the myocardium of patients with coronary heart disease. Siberian medical journal.2018; 33(1): 14-20. doi: 10.29001/2073-8552-2018-33-1-14-20. [In Russian]

30. Bagrij A.Je., Suprun E.V., Mihajlichenko E.S. Chronic heart failure and type 2 diabetes mellitus: state of the problem. Russian Journal of Cardiology. 2020; 25(4): 3858. doi:10.15829/1560-4071-2020-3858 [In Russian]

31. Dedov I.I., Shestakova M.V., Majorov A.Ju. Type 2 diabetes mellitus in adults. Clinical Guidelines. Diabetes mellitus. 2020; 23(S2): 4-102. doi: 10.14341/DM12507. [In Russian].

32. Liu D, Jin B, Chen W, et al. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019; 20: 15. doi:10.1186/s40360-019-0293-y

33. Shumilova N.A., Pavlova S.I. Glyflozins: Glycemic and Non-glycemic Effects. Acta medica Eurasia. 2019; 1: 44-51. doi: acta-medica-eurasica.ru/single/2019/1/6/ [In Russian]

34. Heerspink H.J. L., Stefansson B.V., Chertow G.M. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35: 274–282. doi:10.1093/ndt/gfz290.

35. Lo K.B., Gul F., Ram P. et al. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2020; 10: 1–10. doi:10.1159/000503919.

36. Perkovic V., Jardine M.J., Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-2306. doi: 10.1056/NEJMoa1811744.

37. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol .2019; 7: 776-785. doi:10.1016/S2213-8587(19)30249-9.

38. Ghosh-Swaby O.R., Goodman S.G., Leiter L.A. et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomized cardiovascular outcome trials. Lancet Diabetes and Endocrinology. 2020; 8(5): 418-435. doi:10.1016/S2213-8587(20)30038-3

39. Marso SP, Daniels GH, Brown-Frandsen K et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311–322. doi: 10.1056/NEJMoa1603827

40. Bonora B.M., Avogaro A., Fadini G.P. Extraglycemic effects of SGLT2 Inhibitors: A review of the evidence. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; 13: 161–174. doi: 10.2147/DMSO.S233538

41. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43: 487–493. doi: 10.2337/dci19-0066

42. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020; 41: 407-477. doi:10.1093/eurheartj/ehz425.

43. Mancini GBJ, Boden WE, Brooks MM et al. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: a pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018; 277: 186–194. doi: 10.1016/j.atherosclerosis.2018.04.005

44. Kosiborod M, Arnold SV, Spertus JA et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013; 61: 2038–2045. doi: 10.1016/j.jacc.2013.02.011

45. Mancini GBJ, Boden WE, Brooks MM et al. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: a pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018; 277: 186–194. doi: 10.1016/j.atherosclerosis.2018.04.005

46. Farkouh ME, Domanski M, Dangas GD et al; FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM Follow-On Study. J Am Coll Cardiol. 2019; 73: 629–638. doi: 10.1016/j.jacc.2018.11.001

47. Bhatt DL. CABG the clear choice for patients with diabetes and multivessel disease. Lancet. 2018; 391: 913–914. doi: 10.1016/S0140-6736(18)30424-0

48. Neumann FJ, Sousa-Uva M, Ahlsson A et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165. doi:10.1093/eurheartj/ehy394

49. Doenst T, Haverich A, Serruys P, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019; 73: 964–976. doi: 10.1016/j.jacc.2018.11.053

50. Head SJ, Milojevic M, Daemen J. et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018; 391: 939–948. doi: 10.1016/S0140-6736(18)30423-9